A Phase 2, Open-Label Study to Assess the Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

Trial Profile

A Phase 2, Open-Label Study to Assess the Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Peyronie's disease
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms IMPRESS
  • Most Recent Events

    • 19 May 2015 Results presented at the American Urological Association (AUA) at its 110th Annual Scientific Meeting, as reported by Endo Pharmaceuticals media release.
    • 08 May 2014 According to a BioSpecifics Technologies Corporation media release, a MAA of XIAPEX for the treatment of Peyronie's disease is being processed by SOBI (Swedish Orphan Biovitrium AB).
    • 08 May 2013 Results from a pooled analysis of IMPRESS, IMPRESS-I, and IMPRESS-II presented at the 108th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top